As an incomparable manufacturer of the in vitro diagnostics (IVD) market, Creative Biolabs provides a number of high quality IVD antibodies custom development service for miR-133 marker. Our IVD antibodies are available for the diagnosis of myocardial infarction (MI) and cardiac hypertrophy.
MicroRNAs (miRNAs) are endogenous non-coding RNAs made up of 21-25 nucleotides. By binding to the 3' UTR of target mRNAs, they can modulate protein-coding genes at the posttranscriptional level through degradation of mRNAs or suppression of protein translation. About 700 human miRNAs have been identified until now, and the majority of them were discovered to be tissue-/cell-specific. Increasing evidence showed that miRNAs serve essential roles in a variety of physiological and pathologic processes, and the dysfunctions of miRNAs are closely connected with many diseases and pathophysiologies. Some recent researches indicated that miRNAs were largely existed in body fluid and may be exploited as biomarkers for several diseases. MiR-133, a muscle specific miRNA, is largely expressed in myocardial cells. It has reported that miR-133 serves crucial roles in myogenesis, cardiac development and hypertrophy.
Figure 1. Transcriptional regulatory networks regulated by miR-133 and miR-1 during cardiac muscle differentiation. miR-133 plays an important role in the cardiac progenitor cell proliferation and differentiation. (Gama-Carvalho, M. 2014)
miR-133 Marker of Myocardial Infarction
Acute myocardial infarction (AMI) is the most serious syndrome of coronary heart diseases (CHD) with high morbidity and mortality. Early and accurate diagnosis is crucial for offering appropriate therapy to increase the survival rate and prognosis. Former researches have proven that miR-133 had a low level existence in the plasma of healthy people, and it was presented differentially in different cardiovascular diseases. Recently, a study showed that circulating miR-133 level was observably raised in AMI patients in time-dependent manner, and had a 72.1 fold peak at 21.6 ± 4.5 hours after the onset of AMI symptoms. They also demonstrated that circulating miR-133 was a useful biomarker for CHD, especially for AMI. In addition, its level in plasma enables to reflect the severity of coronary atherosclerosis in CHD patients.
miR-133 Marker of Cardiac Hypertrophy
Left ventricular hypertrophy (LVH) is amplification and hypertrophy of the walls of your left ventricle which is the major pumping chamber of the heart. LVH enables to occur in response to several factors, including high blood pressure or a heart condition which results in the left ventricle to work harder. A recent study has indicated that plasma miR-133 levels were reduced in maintenance haemodialysis (MHD) patients with LVH. Meanwhile, miR-133 levels were negatively correlated with left ventricular mass index (LVMI), implying that the lower miR-133 level, the more obvious LVH. Thus, they suggested that miR-133 may be a blood-based biomarker for cardiac hypertrophy.
With the rapid development of IVD market, IVD antibodies are widely used for the diagnosis of a variety of diseases. Creative Biolabs offers various high-affinity IVD antibody development services for miR-133 marker to meet every customer's requirements. Creative Biolabs also provides other IVD antibodies. Please feel free to contact us for more information and a detailed quote.
Reference
For Research Use Only.
